CL2017001335A1 - Cápsulas blandas de calcifediol. - Google Patents

Cápsulas blandas de calcifediol.

Info

Publication number
CL2017001335A1
CL2017001335A1 CL2017001335A CL2017001335A CL2017001335A1 CL 2017001335 A1 CL2017001335 A1 CL 2017001335A1 CL 2017001335 A CL2017001335 A CL 2017001335A CL 2017001335 A CL2017001335 A CL 2017001335A CL 2017001335 A1 CL2017001335 A1 CL 2017001335A1
Authority
CL
Chile
Prior art keywords
soft capsules
calcifediol
vitamin
deficiency
calcifediol soft
Prior art date
Application number
CL2017001335A
Other languages
English (en)
Inventor
Negre Josep María Sune
Azpitarte Ignacio Ortega
Arenal Barrios Pepa Del
Herrero Gonzalo Hernández
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001335(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of CL2017001335A1 publication Critical patent/CL2017001335A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Paints Or Removers (AREA)
  • Lubricants (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A CÁPSULAS BLANDAS DE CALCIFEDIOL, A SU USO EN EL TRATAMIENTO O LA PREVENCIÓN DE ENFERMEDADES RELACIONADAS CON LA DEFICIENCIA DE VITAMINA D, TALES COMO DEFICIENCIA DE VITAMINA D, DESMINERALIZACIÓN TAL COMO HIPOCALCIEMIA E HIPOFOSFATEMIA, OSTEODISTROFIA RENAL, RAQUITISMO, OSTEOPOROSIS, OSTEOPENIA, OSTEOARTRITIS, OSTEOARTROSIS, OSTEOMALACIA, HIPOPARATIROIDISMO Y ENFERMEDAD INFLAMATORIA DEL INTESTINO, Y A SU PROCEDIMIENTO DE FABRICACIÓN.</p>
CL2017001335A 2015-02-06 2017-05-24 Cápsulas blandas de calcifediol. CL2017001335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382042.8A EP3053598A1 (en) 2015-02-06 2015-02-06 Calcifediol soft capsules

Publications (1)

Publication Number Publication Date
CL2017001335A1 true CL2017001335A1 (es) 2018-01-19

Family

ID=52462260

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001335A CL2017001335A1 (es) 2015-02-06 2017-05-24 Cápsulas blandas de calcifediol.

Country Status (30)

Country Link
US (1) US10525018B2 (es)
EP (3) EP3053598A1 (es)
JP (2) JP6427270B2 (es)
KR (1) KR101971384B1 (es)
CN (2) CN112843014A (es)
AU (1) AU2016214336B2 (es)
BR (1) BR112017010657B1 (es)
CA (1) CA2967170C (es)
CL (1) CL2017001335A1 (es)
CO (1) CO2017004545A2 (es)
CY (1) CY1122976T1 (es)
DK (2) DK3689380T3 (es)
EA (1) EA034821B1 (es)
ES (2) ES2941385T3 (es)
HR (1) HRP20200859T1 (es)
HU (1) HUE050133T2 (es)
LT (1) LT3204047T (es)
MA (2) MA52507A (es)
MD (1) MD3204047T2 (es)
ME (1) ME03739B (es)
MX (1) MX367999B (es)
MY (1) MY189432A (es)
PE (1) PE20170911A1 (es)
PH (1) PH12017501350A1 (es)
PL (1) PL3204047T3 (es)
PT (1) PT3204047T (es)
RS (2) RS64166B1 (es)
SI (1) SI3204047T1 (es)
WO (1) WO2016124724A1 (es)
ZA (1) ZA201703444B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
CN108542908A (zh) * 2018-06-08 2018-09-18 唐飞 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243602A1 (en) * 2020-11-16 2023-09-20 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
WO2022224001A1 (en) 2021-04-22 2022-10-27 Faes Farma, S.A. Universal dosage regime of 25-hydroxy vitamin d3
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
CN114712505B (zh) * 2022-03-10 2023-09-05 南方医科大学南方医院 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用
CN116270520A (zh) * 2023-03-03 2023-06-23 正大制药（青岛）有限公司 一种维生素d胶囊型滴剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532126A (en) 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS6335411A (ja) 1986-07-29 1988-02-16 Tonen Sekiyukagaku Kk 高純度合成石英の製造方法
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
JPH054925A (ja) 1991-06-27 1993-01-14 Teikoku Chem Ind Corp Ltd アルフアカルシドール軟カプセル製剤
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
WO2001015702A1 (fr) * 1999-08-31 2001-03-08 Chugai Seiyaku Kabushiki Kaisha Capsules molles
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
KR20050044655A (ko) 2001-12-03 2005-05-12 노바세아, 인크. 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
WO2003070156A2 (en) 2002-02-20 2003-08-28 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
JP2005531532A (ja) 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
SG110107A1 (en) 2003-09-24 2005-04-28 Bioxell Spa Compound and use in treatment
US20050142185A1 (en) 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20050152969A1 (en) 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
US20050175686A1 (en) 2004-02-11 2005-08-11 Ramachandran Radhakrishnan Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
ZA200610513B (en) 2004-06-07 2008-06-25 Strides Arcolab Ltd Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
BRPI0616330A2 (pt) 2005-09-26 2011-06-14 Novacea Inc prevenÇço e tratamento de distérbios gastrintestinais e da bexiga associados com quimioterapia ou radioterapia usando compostos ativos com vitamina d
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
DK3095447T3 (da) 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
US8501717B2 (en) * 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
PT2321273E (pt) 2008-07-24 2014-12-29 Wisconsin Alumni Res Found Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
WO2012047098A1 (en) 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules

Also Published As

Publication number Publication date
KR101971384B1 (ko) 2019-04-22
DK3204047T3 (da) 2020-06-02
CA2967170A1 (en) 2016-08-11
WO2016124724A1 (en) 2016-08-11
US10525018B2 (en) 2020-01-07
EP3204047A1 (en) 2017-08-16
JP6427270B2 (ja) 2018-11-21
JP6697779B2 (ja) 2020-05-27
BR112017010657B1 (pt) 2022-10-11
ZA201703444B (en) 2019-09-25
US20170348249A1 (en) 2017-12-07
PE20170911A1 (es) 2017-07-12
MA52507A (fr) 2021-03-10
ES2738642T3 (es) 2020-11-06
BR112017010657A2 (pt) 2018-02-14
KR101971384B9 (ko) 2022-07-25
MX367999B (es) 2019-09-12
EP3204047B1 (en) 2020-05-27
RS64166B1 (sr) 2023-05-31
CN112843014A (zh) 2021-05-28
SI3204047T1 (sl) 2020-07-31
EP3053598A1 (en) 2016-08-10
MD3204047T2 (ro) 2020-06-30
MA41058B1 (fr) 2020-05-29
JP2018184458A (ja) 2018-11-22
LT3204047T (lt) 2020-07-10
MX2017006272A (es) 2017-08-14
KR20170093123A (ko) 2017-08-14
CY1122976T1 (el) 2021-10-29
EA201791097A1 (ru) 2017-08-31
EP3689380A1 (en) 2020-08-05
AU2016214336B2 (en) 2017-10-19
RS60467B1 (sr) 2020-07-31
CA2967170C (en) 2018-06-05
EP3689380B1 (en) 2023-03-15
CN106999441A (zh) 2017-08-01
HRP20200859T1 (hr) 2020-08-21
ME03739B (me) 2021-01-20
CO2017004545A2 (es) 2017-08-31
CN106999441B (zh) 2020-11-24
HUE050133T2 (hu) 2020-11-30
EA034821B1 (ru) 2020-03-25
DK3689380T3 (da) 2023-05-22
ES2941385T3 (es) 2023-05-22
JP2017536358A (ja) 2017-12-07
ES2738642T1 (es) 2020-01-24
PL3204047T3 (pl) 2020-08-24
PH12017501350A1 (en) 2017-12-18
PT3204047T (pt) 2020-06-05
MY189432A (en) 2022-02-11
AU2016214336A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
CL2017001335A1 (es) Cápsulas blandas de calcifediol.
MX2022012374A (es) Composiciones multi-suplementos.
HK1248570A1 (zh) D2o穩定化的藥物製劑
ZA201805747B (en) Biologically active cannabidiol analogs
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
IL283837A (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
PL3139904T3 (pl) Formulacja witaminy rozpuszczalnej w tłuszczach
HK1248140A1 (zh) 用於治療癌症或免疫性疾病的細胞外基質組合物
ZA201905380B (en) 1-amino-1-cyclopropanecarboxylic acid hudrochloride formulations
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
ZA201905379B (en) 1-amino-1-cyclopropanecaboxylic acid formulations
HUE060836T2 (hu) A savas rész társkristályait tartalmazó pezsgõkészítmények
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
GB201719987D0 (en) Improvements relating to hypochlorous acid
CL2017000988A1 (es) Proceso de síntesis de hidroxi-triacilgliceroles y usos de los mismos para la prevención y el tratamiento de enfermedades
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN
ITUB20169928A1 (it) Formulazioni farmaceutiche per il trattamento del diabete
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
DK3090638T3 (da) Kosttilskud til behandling af vitamin-d3-mangelsymptomer
HK1253014A1 (zh) 用於治療龐貝氏病的增强的酸性α-葡糖苷酶
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
HK1216367A2 (zh) 男用保健鞋
FR3034309B3 (fr) Kit de reconstruction femorale
IN2014CH00035A (es)